Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Downgrade
Vocera downgraded to Neutral on valuation at Baird » 08:02
01/08/21
01/08
08:02
01/08/21
08:02
VCRA

Vocera

$44.57 /

+1.065 (+2.45%)

, RCM

R1 RCM

$23.74 /

+0.05 (+0.21%)

, PHR

Phreesia

$56.90 /

+1.58 (+2.86%)

, TDOC

Teladoc

$228.86 /

+24.34 (+11.90%)

, TLMD

SOC Telemed

$7.45 /

+0.07 (+0.95%)

Baird analyst Matthew…

Baird analyst Matthew Gillmor downgraded Vocera Communications (VCRA) to Neutral from Outperform with a $40 price target. The analyst cites valuation for the downgrade following the stock's recent appreciation. For healthcare technology, Gillmor continues to favor "high-growth disruptive niches" and believes revenue cycle names like R1 RCM (RCM) and Phreesia (PHR) as well as telehealth names Teladoc (TDOC) and SOC Telemed (TLMD) are the most compelling at the moment.

ShowHide Related Items >><<
VCRA Vocera
$44.57 /

+1.065 (+2.45%)

TLMD SOC Telemed
$7.45 /

+0.07 (+0.95%)

TDOC Teladoc
$228.86 /

+24.34 (+11.90%)

RCM R1 RCM
$23.74 /

+0.05 (+0.21%)

PHR Phreesia
$56.90 /

+1.58 (+2.86%)

VCRA Vocera
$44.57 /

+1.065 (+2.45%)

01/08/21 Baird
Vocera downgraded to Neutral from Outperform at Baird
11/10/20 Stephens
Vocera initiated with an Overweight at Stephens
10/30/20 Piper Sandler
Vocera price target raised to $41 from $28 at Piper Sandler
07/28/20
Fly Intel: Top five analyst upgrades
RCM R1 RCM
$23.74 /

+0.05 (+0.21%)

12/09/20 RBC Capital
R1 RCM price target raised to $27 from $20 at RBC Capital
11/02/20 KeyBanc
R1 RCM price target raised to $24 from $17 at KeyBanc
08/05/20 SVB Leerink
R1 RCM upgraded to Outperform from Market Perform at SVB Leerink
04/20/20 RBC Capital
R1 RCM initiated with an Outperform at RBC Capital
PHR Phreesia
$56.90 /

+1.58 (+2.86%)

01/04/21 Stephens
Brinker, LiveRamp and Vonage among 2021 best ideas at Stephens
12/14/20 Citi
Phreesia price target raised to $59 from $33 at Citi
12/10/20 RBC Capital
Phreesia price target raised to $51 from $33 at RBC Capital
12/10/20 DA Davidson
Phreesia price target raised to $70 from $35 at DA Davidson
TDOC Teladoc
$228.86 /

+24.34 (+11.90%)

01/06/21 BTIG
Teladoc initiated with a Buy at BTIG
12/22/20 Evercore ISI
Teladoc initiated with an In Line at Evercore ISI
12/17/20 Craig-Hallum
Teladoc price target raised to $212 from $200 at Craig-Hallum
12/16/20 Baird
Baird would be a buyer of Teladoc amid weakness caused by Amazon report
TLMD SOC Telemed
$7.45 /

+0.07 (+0.95%)

01/06/21 BTIG
SOC Telemed initiated with a Buy at BTIG
12/01/20 Baird
SOC Telemed a pure-play on acute telehealth, Baird starts at Outperform
11/30/20 Baird
SOC Telemed initiated with an Outperform at Baird
11/25/20
Fly Intel: Top five analyst initiations
VCRA Vocera
$44.57 /

+1.065 (+2.45%)

TDOC Teladoc
$228.86 /

+24.34 (+11.90%)

RCM R1 RCM
$23.74 /

+0.05 (+0.21%)

PHR Phreesia
$56.90 /

+1.58 (+2.86%)

  • 21
    Oct
TDOC Teladoc
$228.86 /

+24.34 (+11.90%)

RCM R1 RCM
$23.74 /

+0.05 (+0.21%)

VCRA Vocera
$44.57 /

+1.065 (+2.45%)

TDOC Teladoc
$228.86 /

+24.34 (+11.90%)

PHR Phreesia
$56.90 /

+1.58 (+2.86%)

TLMD SOC Telemed
$7.45 /

+0.07 (+0.95%)

TDOC Teladoc
$228.86 /

+24.34 (+11.90%)

PHR Phreesia
$56.90 /

+1.58 (+2.86%)

Hot Stocks
R1 RCM announces conversion agreement with Ascension, TowerBrook » 07:31
01/06/21
01/06
07:31
01/06/21
07:31
RCM

R1 RCM

$23.03 /

-0.47 (-2.00%)

R1 RCM announced that it…

R1 RCM announced that it has entered into an agreement with TCP-ASC ACHI Series LLLP, an investment vehicle jointly owned by Ascension Health Alliance and investment funds affiliated with TowerBrook Capital Partners, for the conversion of all of the 8.00% Series A Convertible Preferred Stock held by the joint investment vehicle to common stock. The Preferred Stock, issued in February 2016, was entitled to 8.0% annual payment-in-kind ("PIK") dividends until February 2023, followed by perpetual 8.0% annual cash dividends, and was not redeemable by R1. As part of the conversion agreement, the joint investment vehicle will receive approximately 139.3M shares of common stock and a one-time $105M cash payment. R1 intends to fund the cash payment with cash from its balance sheet. Pro forma for the conversion of the Preferred Stock, Ascension and TowerBrook, through the joint investment vehicle, will collectively own approximately 54%1 of R1's outstanding shares of common stock. The transaction is expected to close later this month, and all the shares of common stock to be issued as part of the transaction will be subject to a one-year lock up scheduled to expire in 2022. Ascension and TowerBrook will retain their seats on R1's Board of Directors.

ShowHide Related Items >><<
RCM R1 RCM
$23.03 /

-0.47 (-2.00%)

RCM R1 RCM
$23.03 /

-0.47 (-2.00%)

12/09/20 RBC Capital
R1 RCM price target raised to $27 from $20 at RBC Capital
11/02/20 KeyBanc
R1 RCM price target raised to $24 from $17 at KeyBanc
08/05/20 SVB Leerink
R1 RCM upgraded to Outperform from Market Perform at SVB Leerink
04/20/20 RBC Capital
R1 RCM initiated with an Outperform at RBC Capital
RCM R1 RCM
$23.03 /

-0.47 (-2.00%)

RCM R1 RCM
$23.03 /

-0.47 (-2.00%)

Over a month ago
Recommendations
R1 RCM price target raised to $27 from $20 at RBC Capital » 08:09
12/09/20
12/09
08:09
12/09/20
08:09
RCM

R1 RCM

$21.82 /

+0.24 (+1.11%)

RBC Capital analyst Sean…

RBC Capital analyst Sean Dodge raised the firm's price target on R1 RCM to $27 from $20 and keeps an Outperform rating on the shares after holding investor meetings with its CEO and CFO. The analyst notes that the discussion revolved around the "increasingly favorable" macro tailwinds, the company's growing pipeline of opportunities inside and outside of its customer base, as well as the management's ongoing tech investments and "significant" remaining margin runway.

ShowHide Related Items >><<
RCM R1 RCM
$21.82 /

+0.24 (+1.11%)

RCM R1 RCM
$21.82 /

+0.24 (+1.11%)

11/02/20 KeyBanc
R1 RCM price target raised to $24 from $17 at KeyBanc
08/05/20 SVB Leerink
R1 RCM upgraded to Outperform from Market Perform at SVB Leerink
04/20/20 RBC Capital
R1 RCM initiated with an Outperform at RBC Capital
04/13/20 SVB Leerink
R1 RCM initiated with a Market Perform at SVB Leerink
RCM R1 RCM
$21.82 /

+0.24 (+1.11%)

RCM R1 RCM
$21.82 /

+0.24 (+1.11%)

Conference/Events
R1 RCM participates in a conference call with SVB Leerink » 10:25
12/02/20
12/02
10:25
12/02/20
10:25
RCM

R1 RCM

$20.80 /

+ (+0.00%)

Conference call with CEO…

Conference call with CEO Flanagan and CFO Wilson will be held on December 2 at 11 am hosted by SVB Leerink.

ShowHide Related Items >><<
RCM R1 RCM
$20.80 /

+ (+0.00%)

RCM R1 RCM
$20.80 /

+ (+0.00%)

11/02/20 KeyBanc
R1 RCM price target raised to $24 from $17 at KeyBanc
08/05/20 SVB Leerink
R1 RCM upgraded to Outperform from Market Perform at SVB Leerink
04/20/20 RBC Capital
R1 RCM initiated with an Outperform at RBC Capital
04/13/20 SVB Leerink
R1 RCM initiated with a Market Perform at SVB Leerink
RCM R1 RCM
$20.80 /

+ (+0.00%)

RCM R1 RCM
$20.80 /

+ (+0.00%)

Conference/Events
R1 RCM participates in a conference call with SVB Leerink » 04:55
12/02/20
12/02
04:55
12/02/20
04:55
RCM

R1 RCM

$20.80 /

+0.55 (+2.72%)

Conference call with CEO…

Conference call with CEO Flanagan and CFO Wilson will be held on December 2 at 11 am hosted by SVB Leerink.

ShowHide Related Items >><<
RCM R1 RCM
$20.80 /

+0.55 (+2.72%)

RCM R1 RCM
$20.80 /

+0.55 (+2.72%)

11/02/20 KeyBanc
R1 RCM price target raised to $24 from $17 at KeyBanc
08/05/20 SVB Leerink
R1 RCM upgraded to Outperform from Market Perform at SVB Leerink
04/20/20 RBC Capital
R1 RCM initiated with an Outperform at RBC Capital
04/13/20 SVB Leerink
R1 RCM initiated with a Market Perform at SVB Leerink
RCM R1 RCM
$20.80 /

+0.55 (+2.72%)

RCM R1 RCM
$20.80 /

+0.55 (+2.72%)

Conference/Events
R1 RCM participates in a conference call with SVB Leerink » 14:59
11/30/20
11/30
14:59
11/30/20
14:59
RCM

R1 RCM

$20.29 /

-0.22 (-1.07%)

Conference call with CEO…

Conference call with CEO Flanagan and CFO Wilson will be held on December 2 at 11 am hosted by SVB Leerink.

ShowHide Related Items >><<
RCM R1 RCM
$20.29 /

-0.22 (-1.07%)

RCM R1 RCM
$20.29 /

-0.22 (-1.07%)

11/02/20 KeyBanc
R1 RCM price target raised to $24 from $17 at KeyBanc
08/05/20 SVB Leerink
R1 RCM upgraded to Outperform from Market Perform at SVB Leerink
04/20/20 RBC Capital
R1 RCM initiated with an Outperform at RBC Capital
04/13/20 SVB Leerink
R1 RCM initiated with a Market Perform at SVB Leerink
RCM R1 RCM
$20.29 /

-0.22 (-1.07%)

RCM R1 RCM
$20.29 /

-0.22 (-1.07%)

Earnings
R1 RCM raises FY20 revenue view $1.25B-$1.26B from $1.22B-$1.25B » 07:07
11/03/20
11/03
07:07
11/03/20
07:07
RCM

R1 RCM

$18.58 /

+0.67 (+3.74%)

Consensus $1.24B. Sees…

Consensus $1.24B. Sees adjusted EBITDA $230M-$240M.

ShowHide Related Items >><<
RCM R1 RCM
$18.58 /

+0.67 (+3.74%)

RCM R1 RCM
$18.58 /

+0.67 (+3.74%)

11/02/20 KeyBanc
R1 RCM price target raised to $24 from $17 at KeyBanc
08/05/20 SVB Leerink
R1 RCM upgraded to Outperform from Market Perform at SVB Leerink
04/20/20 RBC Capital
R1 RCM initiated with an Outperform at RBC Capital
04/13/20 SVB Leerink
R1 RCM initiated with a Market Perform at SVB Leerink
RCM R1 RCM
$18.58 /

+0.67 (+3.74%)

RCM R1 RCM
$18.58 /

+0.67 (+3.74%)

Earnings
R1 RCM reports Q3 EPS 0c, consensus 0c » 07:06
11/03/20
11/03
07:06
11/03/20
07:06
RCM

R1 RCM

$18.58 /

+0.67 (+3.74%)

Reports Q3 revenue…

Reports Q3 revenue $307.2M, consensus $295.38M. "I am incredibly proud of the team's continued dedication in delivering outstanding performance to our customers during these challenging times. Given our learnings over the past several months, we are very well prepared to help customers navigate challenges presented by the pandemic going forward," said Joe Flanagan, President and Chief Executive Officer of R1. "We continue to see strong demand for our solutions and are pleased to have signed end-to-end agreements covering $5 billion in annual net patient revenue to date in 2020, well ahead of the $3 billion target we set at the start of the year."

ShowHide Related Items >><<
RCM R1 RCM
$18.58 /

+0.67 (+3.74%)

RCM R1 RCM
$18.58 /

+0.67 (+3.74%)

11/02/20 KeyBanc
R1 RCM price target raised to $24 from $17 at KeyBanc
08/05/20 SVB Leerink
R1 RCM upgraded to Outperform from Market Perform at SVB Leerink
04/20/20 RBC Capital
R1 RCM initiated with an Outperform at RBC Capital
04/13/20 SVB Leerink
R1 RCM initiated with a Market Perform at SVB Leerink
RCM R1 RCM
$18.58 /

+0.67 (+3.74%)

RCM R1 RCM
$18.58 /

+0.67 (+3.74%)

Recommendations
R1 RCM price target raised to $24 from $17 at KeyBanc » 07:30
11/02/20
11/02
07:30
11/02/20
07:30
RCM

R1 RCM

$17.91 /

-0.05 (-0.28%)

KeyBanc analyst Donald…

KeyBanc analyst Donald Hooker raised the firm's price target on R1 RCM to $24 from $17, while reiterating an Overweight rating on the shares based on a newly visible path for the company to reach $600M of run-rate adjusted EBITDA in the coming years. Last week, RCM signed a 10-year contract to manage about $2.8B of net patient revenue at LifePoint Health, and Hooker sees another $10.5B of NPR from potential expansions at LifePoint Health and Intermountain Health.

ShowHide Related Items >><<
RCM R1 RCM
$17.91 /

-0.05 (-0.28%)

RCM R1 RCM
$17.91 /

-0.05 (-0.28%)

08/05/20 SVB Leerink
R1 RCM upgraded to Outperform from Market Perform at SVB Leerink
04/20/20 RBC Capital
R1 RCM initiated with an Outperform at RBC Capital
04/13/20 SVB Leerink
R1 RCM initiated with a Market Perform at SVB Leerink
03/26/20 Cowen
Cowen sees three healthcare IT names poised for rebound
RCM R1 RCM
$17.91 /

-0.05 (-0.28%)

RCM R1 RCM
$17.91 /

-0.05 (-0.28%)

Hot Stocks
R1 RCM, LifePoint Health partner for revenue cycle management agreement » 08:16
10/28/20
10/28
08:16
10/28/20
08:16
RCM

R1 RCM

$17.52 /

+0.43 (+2.52%)

R1 RCM and LifePoint…

R1 RCM and LifePoint Health have entered into a new revenue cycle management agreement that will make R1 the exclusive revenue cycle management partner for more than one-third of LifePoint hospitals. The comprehensive partnership is designed to enhance patient experience and streamline operations to meet the evolving needs of the health system now and into the future for the communities LifePoint serves.

ShowHide Related Items >><<
RCM R1 RCM
$17.52 /

+0.43 (+2.52%)

RCM R1 RCM
$17.52 /

+0.43 (+2.52%)

08/05/20 SVB Leerink
R1 RCM upgraded to Outperform from Market Perform at SVB Leerink
04/20/20 RBC Capital
R1 RCM initiated with an Outperform at RBC Capital
04/13/20 SVB Leerink
R1 RCM initiated with a Market Perform at SVB Leerink
03/26/20 Cowen
Cowen sees three healthcare IT names poised for rebound
RCM R1 RCM
$17.52 /

+0.43 (+2.52%)

RCM R1 RCM
$17.52 /

+0.43 (+2.52%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.